Korro Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 4, 2023--
Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer and President, will present at the 41 st Annual J.P. Morgan Healthcare Conference, being held January 9-12, 2023 in San Francisco, CA.
Date: Tuesday, January 10, 2023
Time: 9:30 a.m. PT – 9:55 a.m. PT
About Korro Bio, Inc.
Korro is an RNA editing company focused on discovery and development of a new class of precision genetic medicines. Korro’s proprietary and modular platform, OPERA™, combines data-driven design with off-the-shelf chemistry and delivery to achieve highly selective RNA editing. This unique technology enables the functional benefits of gene therapy with a transient, repeated-administration regimen that permits pharmacologic titration of therapeutic efficacy and safety, in a cost-effective drug product. As a result, Korro’s portfolio of innovative RNA therapies has the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is located in Cambridge, Mass. For more information, visit korrobio.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230104005708/en/
CONTACT: For further details:Investors
Ten Bridge Communications
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS
INDUSTRY KEYWORD: GENETICS SCIENCE HEALTH RESEARCH
SOURCE: Korro Bio, Inc.
Copyright Business Wire 2023.
PUB: 01/04/2023 10:26 AM/DISC: 01/04/2023 10:26 AM